127985-74-4
127985-74-4
Chemical Structure
p-SCN-Bn-DOTA
- CAS No.: 127985-74-4
- Formula:C24H33N5O8S
- Molecular Weight:551.61
IUPAC Name: 2,2',2'',2'''-(2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid
InChIKey: UDOPJKHABYSVIX-UHFFFAOYSA-N
SMILES: O=C(O)CN1C(CC2=CC=C(N=C=S)C=C2)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1
Biological Activity: p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
p-SCN-Bn-DOTA | 99.78% | p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
p-SCN-Bn-DOTA (Standard) | ≥98% | p-SCN-Bn-DOTA (Standard) is the analytical standard of p-SCN-Bn-DOTA. This product is intended for research and analytical applications. p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 1.00
HY-156038(S)-p-SCN-Bn-DOTA -
Similarity Score 0.89
HY-48876p-NH2-Bn-DOTA -
Similarity Score 0.89
HY-W038001DOTA-benzene -
Similarity Score 0.89
HY-178221(S)-P-SCN-BN-NOTA -
Similarity Score 0.89
HY-178271P-SCN-Bn-NOTA -
Similarity Score 0.88
HY-W782083p-SCN-Bn-NOTA trihydrochloride -
Similarity Score 0.85
HY-W782075p-NO2-Bn-DOTA -
Similarity Score 0.83
HY-W782081p-SCN-Bn-oxo-DO3A -
Similarity Score 0.80
HY-201263p-SCN-Bn-TCMC -
Explore the MedChemAI to find more analogs
References
- [1]. Vera DRB, et, al. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 2011 Jun;26(3):287-97. [Content Brief]
- [2]. Giannini G, et, al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253. [Content Brief]
